In-house manufacturing is an essential component of our strategy and our vision to transform treatment of serious diseases.
We believe that leveraging our internal manufacturing capabilities, along with expertise from contract manufacturing organizations (CMOs), when needed, facilitates our growth and enhances our ability to secure drug substance for current and future development activities. We also believe that these capabilities support potential for commercial manufacturing.
Through our internal current good manufacturing practices (cGMP) manufacturing capabilities, located in a 90,000 square foot facility in Lexington, Massachusetts, we have the capacity to support multiple discovery, preclinical, and early clinical-stage programs and have the established expertise to efficiently conduct manufacturing runs for oligonucleotides across a spectrum of modalities.
Our cGMP manufacturing capabilities include
Onsite process development, analytical development, quality control, and quality assurance
Oligonucleotide synthesis capacity ranging from high throughput to large-scale GMP manufacturing
Comparable yield and cost-of-goods to standard stereorandom oligonucleotides
Industry standard equipment
GMP manufacturing capacity that can be made available to partners